Loading company…
Versanis Bio developed therapies for obesity and cardiometabolic diseases using research into activin and incretin biology.
Founded in 2020 and based in New York, US, Versanis Bio developed treatments for obesity and cardiometabolic diseases. Its research targeted activin type II receptors in fat and muscle cells to influence metabolism and body composition. Eli Lilly and Company agreed to acquire the company in July 2023 for USD 1.925 bn, including upfront and future milestone payments.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in